## 1 **Title**

2 Systematic mediation and interaction analyses of kidney function genetic loci in a general 3 population study.

4

## 5 **Authors**

- 6 Dariush Ghasemi-Semeskandeh<sup>1,2,3\*</sup>, David Emmert<sup>1</sup>, Eva König<sup>1</sup>, Luisa Foco<sup>1</sup>, Martin Gögele<sup>1</sup>,
- 7 Laura Barin<sup>1</sup>, Ryosuke Fujii<sup>1,4,5</sup>, Christian Fuchsberger<sup>1</sup>, Dorien J.M. Peters<sup>2</sup>, Peter P. 8 Pramstaller<sup>1</sup>, Cristian Pattaro<sup>1\*</sup>

9

# 10 **Affiliations**

- 11 <sup>1</sup> Institute for Biomedicine, Eurac Research, Bolzano, Italy
- 12 <sup>2</sup> Department of Human Genetics, Leiden University Medical Center, Leiden, The Netherlands
- 13 <sup>3</sup> Health Data Science Centre, Human Technopole, Milan, Italy
- 14 <sup>4</sup> Department of Preventive Medical Sciences, Fujita Health University School of Medical
- 15 Sciences, Toyoake, Japan
- 16 <sup>5</sup> Department of Preventive Medicine, Nagoya University Graduate School of Medicine, Nagoya,
- 17 Japan

18

# 19 **\* Corresponding authors**

- 20 Dariush Ghasemi-Semeskandeh
- 21 Human Technopole, Health Data Science Centre
- 22 V.le Rita Levi-Montalcini, 1, Milan 20157, Italy.
- 23 email: ghasemi.dariush@yahoo.com
- 24
- 25 Cristian Pattaro
- 26 Eurac Research Institute for Biomedicine,
- 27 Via Volta 21, 39100 Bolzano, Italy
- 28 Tel. +39 0471 055 527
- 29 email: cristian.pattaro@eurac.edu

#### 31 **Abstract**

32 Chronic kidney disease (CKD) is a complex disease affecting >10% of the global population, 33 with large between- and within-continent variability reflecting major environmental effects. To 34 identify molecular targets for treatment, genome-wide association study meta-analyses 35 (GWAMAs) of CKD-defining traits have identified hundreds of genetic loci in aggregated 36 populations. However, while GWAMAs estimate the average allelic effect across studies, single 37 population studies may be relevant to unravel specific mechanisms. To assess whether an 38 individual study from a specific population could extend existing knowledge on kidney function 39 genetics, we selected 147 kidney function relevant loci identified by a large GWAMA, assessing 40 their association with the glomerular filtration rate estimated from serum creatinine (eGFRcrea) 41 in the Cooperative Health Research In South Tyrol (CHRIS) study (n=10,146), conducted in an 42 Alpine region where thyroid dysfunction is common. We replicated associations with single 43 nucleotide polymorphisms (SNPs) at 11 loci, showing up-to-5.4 times larger effect sizes than in 44 the corresponding GWAMA, not explainable by minor allele frequency differences. Systematic 45 mediation analysis across 70 quantitative traits identified serum magnesium and the activated 46 partial thromboplastin time as partial mediators of the eGFRcrea associations at *SHROOM3* 47 and *SLC34A1*, respectively. Given that free triiodothyronine and thyroxine were effect modifiers 48 across all loci, we conducted SNP-by-thyroid stimulating hormone (TSH) interaction analyses, 49 identifying significant interactions at *STC1*: SNPs had larger effects on eGFRcrea at higher TSH 50 levels, possibly reflecting stanniocalcin-1 autocrine and paracrine role. Individual population 51 studies can help characterize genetic associations. The interplay between phenotypes at 52 *SHROOM3* and *SLC34A1* and the role of thyroid function as a genetic effect modifier warrant 53 further investigations.

#### 54 **Introduction**

55 Chronic kidney disease (CKD) is a common complex disease that increases the risk of kidney 56 failure, cardiovascular mortality, and all-cause mortality<sup>1</sup>. CKD is predicted to become the 5<sup>th</sup> 57 leading cause of death by  $2040^2$ . While affecting  $>10\%$  of the population globally, CKD 58 prevalence shows marked variability across countries, both between and within continents<sup>3</sup>. 59 Between-continent variability is likely guided by combinations of environmental and genetic 60 differences, such as is the case with sickle cell trait and albuminuria<sup>4</sup>. Within-continent variability 61 could be more related to environmental differences, including lifestyle, public health policies,  $62$  and assessment methods<sup>4,5</sup>.

63 To unravel the genetic basis of CKD, several genome-wide association study meta-64 analyses (GWAMAs) were conducted that analyzed the CKD-defining marker glomerular 65 filtration rate (GFR) estimated from serum creatinine (eGFRcrea) $6$ . More than 400 associated 66 loci have been identified to date<sup>7</sup>. While GWAMAs estimate the average allelic effect across 67 studies, evidence shows that individual population studies may be extremely relevant to 68 advance discoveries not only in the field of rare diseases<sup>8</sup> but also with regard to markers of 69 common chronic diseases such as triglycerides and low density lipoprotein (LDL) cholesterol<sup>9</sup>, 70 age at diabetes onset<sup>10</sup>, and mood disorders<sup>11</sup>. The evidence accumulated so far suggests that 71 there is no general rule and that the contribution of an individual study to the dissection the 72 biological basis of common phenotypes can only be assessed on a case-by-case basis and 73 depends on study-specific characteristics.

74 Here we analyzed genetic associations with eGFRcrea in the Cooperative Health 75 Research In South Tyrol (CHRIS) study, a general population study conducted in a 76 mountainous region of central Europe<sup>12</sup>. A sample from this same population was previously 77 instrumental to identify genetic linkage of serum creatinine with the *APOL1-MYH9* locus<sup>13</sup> and to 78 replicate common variants associated with eGFRcrea<sup>14</sup>. Characteristics of the geographical 79 region where the study was conducted include the demographic stability over time<sup>15</sup>, the rural 80 environment, and a high frequency of hypothyroidism, typical of mountainous regions<sup>16</sup>. Aim of 81 our analysis was to assess whether this particular study sample could provide information that 82 extend current knowledge on kidney function genetics, by leveraging on local specific 83 characteristics.

84 For a given single population study, with a relatively limited sample size, to help expand 85 knowledge on loci already identified by a large consortium, it is necessary and appropriate to 86 limit investigation to the subset of loci associated with the phenotype of interest in the given

87 study. Thus, we first identified which, among 147 loci found to be associated with kidney 88 function in a large GWAMA from the CKDGen Consortium<sup>17</sup>, were associated with eGFRcrea in 89 the CHRIS study. We take it for granted that the identified loci are relevant for kidney function. 90 This was demonstrated by Wuttke et al.<sup>17</sup> through the combined analysis of eGFRcrea and 91 blood urea nitrogen (BUN).

92 CKDGen loci were tested for replication in the CHRIS study. The purpose of this 93 replication analysis was to identify those loci for which a study of limited size can try to 94 contribute new information. The replication analysis should not be understood as a 95 demonstration of the validity of the analyzed loci: in fact, they should already be considered as 96 validated, as they were identified through a large meta-analysis on more than 760,000 97 individuals and replicated in an independent study on more than 280,000 individuals<sup>17</sup>.

98 The features of the replicated loci were then assessed against corresponding European 99 ancestry CKDGen GWAMA results. Given that several replicated loci showed larger effects in 100 CHRIS than in the European ancestry CKDGen GWAMA, we examined the possible reasons of 101 such larger effects and conducted extensive mediation analyses across 70 quantitative 102 biochemical and anthropometric traits, reflecting multiple health conditions. Further, after 103 observing a systematic modification of the genetic association with eGFRcrea when adjusting 104 for thyroid-related traits, we conducted SNP-by-thyroid function interaction analyses. The aims 105 of the mediation and the interaction analyses were to identify the presence of intermediate 106 phenotypes and effect modifiers, respectively, that were specific of the study sample.

107

108

#### 109 **Methods**

### 110 *Study sample*

111 The present analyses were based on 10,146 individuals with complete genotype data who 112 participated to the CHRIS study, a population-based study conducted in South Tyrol, Italy, 113 between 2011 and 2018, which has been extensively described elsewhere<sup>12,18</sup>. Briefly, 114 participants underwent blood drawing, urine collection, anthropometric measurements, and 115 clinical assessments early in the morning, after an overnight fast. Medical history was 116 reconstructed through interviewer- and self-administered standardized questionnaires. Drug 117 treatment was identified via barcode scan of the drug containers that participants were

118 instructed to bring at the study center visit, with the drug code linked to an official drug 119 databan $k^{12}$ .

120

## 121 *eGFRcrea estimation*

122 Serum creatinine (SCr) was measured with a colorimetric assay on Roche Modular PPE 123 (n=4,176) and Abbott Diagnostic Architect c16000 (n=5,970) instrumentations. According to 124 previous analyses<sup>18</sup>. SCr was normalized by instrument (fixed effect) and participation period 125 (random effect) using a linear mixed model implemented in the 'lme4' R package<sup>19</sup>. To reflect 126 the same methods used in the CKDGen Consortium meta-analysis<sup>17</sup>, eGFRcrea was estimated 127 using the 2009 CKD-EPI equation<sup>20</sup> implemented in the R package 'nephro' v1.2<sup>21</sup> and 128 winsorized at 15 and 200 ml/min/1.73 $m^2$ . Finally, the natural logarithm transformation was 129 applied.

130

### 131 *Genotype imputation*

132 Genotyping was performed in two batches using genotyping array chips based on the Illumina 133 Human Omni Microarray platform. Following quality control analysis, the two data batches were 134 merged, phased with SHAPEIT2 v2.r837, using the duoHMM method (--duohmm -W 5) with 800 135 states and 30 rounds<sup>22</sup>, and imputed based on the TOPMed r2 standard reference panel on the 136 Michigan Imputation Server<sup>23</sup>. We obtained 34,084,280 SNPs with minimum imputation quality 137 index Rsq ≥0.3 and minor allele count (MAC) ≥1, aligned with human genome assembly<br>138 GRCh38. A genetic relatedness matrix (GRM) was obtained from the autosomal genotyped GRCh38. A genetic relatedness matrix (GRM) was obtained from the autosomal genotyped 139 SNPs using EPACTS v3.2.6 modified for compatibility with assembly GRCh38. Genetic principal 140 components (PCs) were estimated based on the genotyped variants data with minor allele 141 frequency (MAF)  $>0.05$  using GCTA<sup>24</sup>.

142

### 143 *GWAS and replication of CKDGen results*

144 We conducted a GWAS of age- and sex-adjusted residuals of ln(eGFRcrea) using the EMMAX 145 method<sup>25</sup> implemented in EPACTS v3.2.6, including the GRM to model the sample structure. 146 After the analysis, we removed variants with minor allele frequency (MAF) <0.005, leaving 147 10,158,100 SNPs for further characterization. Genomic inflation was assessed on this set of 148 SNPs by estimating the genomic control factor  $\lambda^{26}$ .

149 Summary statistics from the CKDGen GWAMA $17$  were downloaded from the publicly 150 available repository at https://ckdgen.imbi.uni-freiburg.de. Given a subset of 4661 samples from 151 the CHRIS study was previously included in the CKDGen GWAMA, we removed CHRIS data 152 from the CKDGen GWAMA summary statistics using MetaSubtract v1.60 $^{27}$ . After this process, 153 the 147 variants remained genome-wide significant in CKDGen. We lifted the CKDGen genomic 154 positions from the GRCh37 to the GRCh38 map, using CrossMap  $v0.5.3^{28}$ .

155 Given small-sample bias can cause large effect estimate fluctuations and given it is not 156 uncommon to observe small studies with opposite effect directions compared to the meta-157 analysis results in large GWAMAs, to ensure consistency of the effect direction, replication of 158 the 147 loci in CHRIS was assessed based on a one-sided test, following common practice<sup>29</sup>. 159 Statistical significance for replication was set at the Bonferroni-corrected level of 0.00034 160 (0.05/147), for any variant in strong linkage disequilibrium (LD) ( $r^2$ >0.8) with a lead CKDGen 161 variant. LD was estimated using emeraLD v0.1 $^{30}$ . The total number of SNPs within the 147 loci 162 was 6337. Adjustment for 147 independent tests covers 98% of the SNP's cumulative variance 163 (Suppl. Fig. S1).

164 We compared the variance of ln(eGFRcrea) explained by SNPs in CHRIS versus 165 CKDGen European Ancestry analysis as  $b^2 \times 2 \times p \times (1-p)$  / var(y),<sup>17</sup> where y is the age- and 166 sex-adjusted ln(eGFRcrea), b is the estimated SNP effect on y, and p is the SNP allele 167 frequency. For comparison with CKDGen, we used a common estimate of  $var(y)$ .

168

#### 169 *Mediation analysis*

170 Replicated ln(eGFRcrea)-SNP associations were submitted to mediation analysis across 70 171 quantitative anthropometric, blood pressure and biochemical traits (listed in Supplementary 172 Table S1), following the flowchart represented in Fig. 1. SCr was included as a positive control. 173 To prevent potential measurement instrument effects<sup>18</sup>, we applied quantile normalization to 174 each trait (Supplementary Methods). Mediation analysis was conducted for each *trait* following 175 the established 4-step framework and fitting linear regression models throughout:

176 1. In(eGFRorea) = 
$$
\beta_1
$$
 SNP + $\sum_i^K \theta_i X_i$  +  $\varepsilon_1$ 

177 2. In(eGFRcrea) = 
$$
\beta_2
$$
 SNP +  $\gamma_2$  trait +  $\sum_i^K \theta_i X_i$  +  $\varepsilon_2$ 

- 178 3. *trait* =  $\beta_3$ SNP + $\sum_i^R \theta_i X_i + \varepsilon_3$
- 179 4. *trait* =  $\beta_4$ SNP +  $\delta_4$ In(eGFRcrea) +  $\sum_i^K \theta_i X_i$  + $\varepsilon_4$

180 where  $\varepsilon_1$  to  $\varepsilon_4$  refer to Gaussian error terms, and  $\sum_i^K \theta_i X_i$  indicate the inclusion of K covariates, -181 namely age, sex, the first 10 genetic PCs and an intercept. Fitting PC-adjusted simple linear 182 models came for practical reasons after observing substantial equivalence with kinship-adjusted 183 linear mixed models obtained with EMMAX (Suppl. Fig. S2). Step 1 corresponds to the GWAS 184 results: given we investigated the replicated variants, the estimate of  $\beta_1$  (b<sub>1</sub>) was always<br>185 significant. We defined two criteria that must be satisfied in order for a trait to be considered at significant. We defined two criteria that must be satisfied in order for a trait to be considered at 186 least a partial mediator of the ln(eGFRcrea)-SNP relation: (i) evidence of a substantial alteration 187 of the SNP effect on ln(eGFRcrea) when adjusting for the trait (step 2) and (ii) the SNP is also 188 associated with the trait (step 3) at a multiple-testing corrected level of 6.5 $\times$ 10<sup>-5</sup> (corresponding 189 to 0.05 / (70 traits  $\times$  11 independent loci)). Criterion (i) was assessed by analyzing the 189 to 0.05 / (70 traits  $\times$  11 independent loci)). Criterion (i) was assessed by analyzing the <br>190 distribution of the estimate of  $\beta$ , (b<sub>2</sub>): for a specific trait, b<sub>2</sub> was classified as an outlier according 190 distribution of the estimate of  $\beta_2$  (b<sub>2</sub>): for a specific trait, b<sub>2</sub> was classified as an outlier according<br>191 to the rule b<sub>2</sub> < P<sub>10</sub> – 1.5 (P<sub>75</sub> – P<sub>25</sub>) or b<sub>2</sub> > P<sub>90</sub> + 1.5 (P<sub>75</sub> – P<sub>25</sub>), where P<sub>10</sub>, P to the rule  $b_2 < P_{10} - 1.5$  (P<sub>75</sub> – P<sub>25</sub>) or  $b_2 > P_{90} + 1.5$  (P<sub>75</sub> – P<sub>25</sub>), where P<sub>10</sub>, P<sub>25</sub>, P<sub>75</sub>, and P<sub>90</sub> 192 indicate the 10<sup>th</sup>, 25<sup>th</sup>, 75<sup>th</sup>, and 90<sup>th</sup> percentile of the distribution of b<sub>2</sub> across all traits. This is 193 essentially a more stringent version of the Tukey's rule for outlier detection.

194 To support associations in step 3 and assess whether lack of mediation evidence might 195 have been due to lack of power in the CHRIS study, we interrogated the SNP-trait associations 196 that passed the mediation analysis step 2 on the PhenoScanner  $v2^{31}$ 197 (http://www.phenoscanner.medschl.cam.ac.uk/, interrogated on 31-Jan-2023), GWAS Catalog<sup>32</sup> 198 (https://www.ebi.ac.uk/gwas/docs/api; 24-Feb-2023), and the ThyroidOmics Consortium 199 summary statistics<sup>33</sup> (https://www.thyroidomics.com), for associations at  $P<5.0\times10^{-8}$ .

200

#### 201 *Interaction with thyroid function phenotypes*

202 Free triiodothyronine (FT3) and thyroxine (FT4) did not qualify as mediators but caused a major 203 departure of  $b_2$  from its expected distribution (see Results). These traits may reflect thyroid 204 gland issues. Given the relevance of hypothyroidism in the region, we analyzed these traits in 205 detail. Because FT3 and FT4 levels were measured only when the thyroid stimulating hormone 206 (TSH) level was <0.4 or >3.8 µUI/mL, we started with a series of sensitivity analyses to exclude 207 the presence of underlying sample stratification. First, we tested whether the distribution of the 208 genotypes was different between individuals with and without measured FT3 and FT4, using a 209 two-sided Wilcoxon test at a significance level of 0.05. Second, to verify whether there was any 210 geographical cluster of individuals with extreme TSH levels (and so measured FT3 and FT4

211 levels), which might have implicated population stratification, we further adjusted the 212 ln(eGFRcrea)-SNP association model in step 1 for municipality of residence.

213 After excluding the presence of sample stratification, we tested the interaction between 214 the SNPs and TSH levels, which were measured in the whole sample. We excluded 416 215 individuals reporting any condition among thyroid cancer (n=16), kidney cancer (n=1), goiter 216 (n=277), having undergone surgery to the thyroid gland (n=312), or having both missing TSH 217 measurement and therapy information (n=4), leaving 9730 individuals for the interaction 218 analysis. Regression models included both the main and the interaction effect terms and were 219 adjusted for the same covariates used in the step 1 model. In addition to quantitative TSH 220 levels, we also tested interaction with broadly defined hyper- and hypothyroidism. 221 Hyperthyroidism was defined as a TSH level of  $< 0.4$   $\mu$ UI/mL or use of thiamazole (n=3) or 222 propylthiouracil (n=1). Hypothyroidism was defined as TSH levels >3.8 µUI/mL or reported use 223 of levothyroxine sodium (n=512). No other thyroid-related treatment was reported. The 224 statistical significance level for interaction testing was set at 0.0045=0.05/11 loci.

225

#### 226 *Ethical statement*

227 The CHRIS study was approved by the Ethical Committee of the Healthcare System of the 228 Autonomous Province of Bozen/Bolzano, protocol no. 21/2011 (19 Apr 2011). All participants 229 provided written informed consent. All the methods were performed in strict accordance with the 230 approved protocol.

- 231
- 232

#### 233 **Results**

234 In the study sample, the median age was 46.5 years (interquartile range, IQR: 32.8, 57.6), 235 females were 55%, and the median eGFRcrea level was 92.2 (IQR: 81.3, 103.2) ml/min/1.73m<sup>2</sup> 236 (Table 1; additional clinical characteristics are reported in Supplementary Table S1). The 237 genomic inflation factor λ was 1.02 (Supplementary Fig. S3), supporting appropriate modeling of<br>238 the sample structure. In the CHRIS study, we replicated 11 of the 147 CKDGen loci (1-sided Pthe sample structure. In the CHRIS study, we replicated 11 of the 147 CKDGen loci (1-sided P-239 value between  $3.34\times10^{-4}$  and  $4.51\times10^{-7}$ ; Table 2; Supplementary Table S2). For each replicated 240 Iocus we retained all variants in LD ( $r^2$ >0.8) with the lead SNP, totaling 163 variants over the 11 241 loci (Supplementary Table S3). The replicated loci displayed very similar LD pattern in CHRIS

242 as in CKDGen (Supplementary Fig. S4). Among the replicated loci, variants' effect magnitude at 243 *CASZ1*, *DDX1*, *PIP5K1B*, *GAB2*, and *IGF1R* was significantly larger in CHRIS than in CKDGen 244 (Fig. 2; Table 2). Replicated loci explained a larger proportion of ln(eGFRcrea) variance (Fig. 245 3A). For them, the CHRIS-to-CKDGen effect ratio varied between 1 and 5.4 and was not 246 entirely explained by MAF differences (Fig. 3B; Supplementary Table S3). Three broad 247 groupings characterized by MAF and effect size differences could be distinguished:

- 248 1. at *PDILT*, *SLC34A1* and *SHROOM3*, we observed similar effect magnitude, 249 regardless whether MAF was similar or lower in CHRIS, consistent with the fact that 250 these loci were amongst the ones identified by the earliest GWAS thanks to their 251 large effects, counterbalancing the still relatively limited sample sizes and the 252  $\log_{10}$  coarser genomic imputation<sup>34,35</sup>;
- 
- 253 2. at *DAB2*, *TMEM60*, *PIP5K1B*, *GAB2*, and *IGF1R*, MAF was similar or slightly larger 254 in CHRIS (effects in CHRIS were 1.3-to-5 times larger than in CKDGen);
- 255 3. at *STC1*, *DDX1*, and *CASZ1*, we observed lower MAF in CHRIS and about 1.8-to-5.4 256 **times larger effects in CHRIS.**
- 257

# 258 *Mediation analysis*

259 To identify possible reasons for observed larger effects, we conducted mediation 260 analysis of the association between eGFRcrea and each of the 163 variants at the 11 loci 261 across 70 quantitative health traits available in CHRIS (Supplementary Table S1). Adjusting the 262 eGFRcrea-SNP association for each trait in turn (step 2 of the mediation analysis; see Methods) 263 resulted in a substantial change of the eGFRcrea-SNP association coefficient in between 4 and 264 12 variant-trait associations per locus (Fig. 4). As expected, adjustment for the positive control 265 SCr resulted in the nearly complete knockdown of the SNP effect at all loci (effect sizes toward 266 null). Often, the effect change happened when adjusting for traits closely related to kidney 267 function such as urate (*GAB2*, *IGF1R*, *PIP5K1B*, *SHROOM3*, and *STC1*), urinary creatinine 268 (*SHROOM3*), and urinary albumin (*IGF1R*). Serum electrolytes such as magnesium 269 (*SHROOM3*), corrected calcium (*PIP5K1B*), and sodium (*DDX1*, *GAB2*, *RSBN1L*, *SLC34A1*, 270 and *STC1*) were also widely involved. Of note was the widespread effect of FT3, FT4, and the 271 activated partial thromboplastin time (aPTT) across all loci. When adjusting for FT3 and FT4, 272 the SNP effect on In(eGFRcrea) was often completely altered. This behavior across all loci may 273 suggest the presence of either a measurement artifact or a general related condition affecting 274 the underlying population.

 $275$  In the  $3<sup>rd</sup>$  mediation analysis step, we evaluated whether the traits identified as effect 276 modifiers in step 2 were associated with the SNP of which they modified the association with 277 eGFRcrea (Table 3; Supplementary Table S4): SNP rs3812036 at *SLC34A1* was associated 278 with aPTT levels (P=3.54×10<sup>-6</sup>) and five SNPs at *SHROOM3* were associated with serum 279 magnesium levels ( $P$ -values between  $5.33 \times 10^{-5}$  and  $6.12 \times 10^{-5}$ ). Three of our associations 280 reproduce previously reported associations found using Phenoscanner: at *SLC34A1*, Tang *et*  281 *al.*<sup>36</sup> reported association of rs3812036 with aPTT (P=2.88×10<sup>-18</sup>), and at *SHROOM3*, Meyer *et* 282  $aI^{37}$  reported associations of magnesium with rs4859682 ( $P=2.39\times10^{-9}$ ) and rs13146355 283 ( $P=6.27\times10^{-13}$ ).

284 All SNP-trait associations that successfully passed the  $2^{nd}$  mediation analysis step were 285 also interrogated against the Phenoscanner, GWAS Catalog, and ThyroidOmics consortium 286 generalts (Methods) to identify associations that might have been missed by the  $3^{rd}$  step of the 287 mediation analysis in CHRIS due to lack of power (Supplementary Table S4). This analysis 288 provided additional support for our findings at *SHROOM3* and *SLC34A1*. It also showed 289 associations between variants at *IGF1R* and serum urate, unraveling how this additional 290 mediation was likely missed by our study due to lack of power.

291 In summary, aPTT and serum magnesium qualified as partial mediators of eGFRcrea 292 associations at *SLC34A1* and *SHROOM3*, respectively. At *SLC34A1*, the partial mediation of 293 aPTT corresponded to a 21% larger effect of the SNP on ln(eGFRcrea); at *SHROOM3*, the 294 partial mediation of serum magnesium corresponded to an effect attenuation of about 11% 295 (Table 3).

296

#### 297 *Interaction with thyroid dysfunction*

298 Despite the pervasive effect change caused by FT3 and FT4 in step-2 analysis, these 299 two traits did not result in significant step-3 associations and so did not qualify as mediators. 300 However, motivated by the fact that hypothyroidism is amongst the leading causes of 301 bospitalization in the region<sup>38</sup>, thyroid problems are common in Alpine areas, and the FT3 and 302 FT4 adjustment affected the SNP-eGFRcrea association at all 11 loci, we considered it 303 reasonable to evaluate a potential role of thyroid dysfunction as a modifier of the SNP-304 eGFRcrea relation.

305 Preliminarily, given that in the CHRIS study FT3 and FT4 were measured only in 306 individuals with TSH levels above or below specific thresholds, we first conducted sensitivity

307 analyses to exclude the presence of artifacts. We did not observe any genotype stratification by 308 measured versus unmeasured FT3 and FT4 levels (Supplementary Table S5). Adjustment for 309 municipality of residence, to exclude the presence of local clusters of thyroid dysfunction, did 310 not alter the results (Supplementary Fig. 3).

311 We then tested for the presence of linear interaction with TSH levels, which identified a 312 significant interaction at *STC1* SNPs rs819185 (*P*=0.00177) and rs819196 (*P*=0.00154) both 313 below the multiple testing threshold of 0.05/11 loci (Fig. 5; Supplementary Table S6). Since for 314 most loci the adjustment both for FT3 and for FT4 were causing an increase of the effect 315 magnitude, we also postulated a U-shaped interaction model, with the SNP effects on 316 ln(eGFRcrea) being larger both in hyper- and in hypothyroidism. We classified individuals as 317 healthy (88.5%), with hypothyroidism (9.8%) or with hyperthyroidism (1.7%; Table 1). Our 318 results did not support the presence of interaction with these two conditions at any locus after 319 multiple testing control, despite nominally significant *P*-values observed for interaction between 320 hyperthyroidism and SNPs in *SHROOM3* (*P*=0.03) and between hypothyroidism and SNPs in 321 *PIP5K1B* (*P*=0.03) and *GAB2* (*P*=0.04; Supplementary Table S7).

- 322
- 323

### 324 **Discussion**

325 Out of 147 loci known for their association with kidney function, our analysis identified 11 that 326 were more strongly associated with eGFRcrea in the CHRIS study sample than in average 327 European-ancestry population samples. Observed differences in effect magnitude could not be 328 explained by MAF differences. Extensive mediation analysis identified serum magnesium and 329 aPTT as partial mediators of the association of eGFRcrea with variants at *SHROOM3* and 330 *SLC34A1*, respectively. SNP-by-TSH interaction analysis highlighted that the effect of variants 331 at *STC1* on eGFRcrea would vary by TSH levels.

332 *PDILT*, *SHROOM3*, and *SLC34A1* explained the same fraction of eGFRcrea variance in 333 CHRIS and CKDGen. In fact, for these loci, a relatively small sample size proved to be sufficient 334 for their detection.<sup>34,35</sup> For all other replicated loci, the replication was due to an interplay 335 between allele frequency differences and effect estimate differences. Figures 3A and 3B show 336 that the effect difference was probably more relevant than the allele frequency differences. But 337 the question remains as to why precisely these and no other loci showed such large effects in 338 CHRIS. SNPs may show larger effects at lower MAF. This situation was observed at just *DDX1*

339 and *CASZ1*, whose effects got larger as the CHRIS-to-CKDGen MAF ratio got smaller. 340 However, the MAF difference was unrelated to the larger effects observed at *GAB2*, *TMEM60*, 341 *PIP5K1B*, and *IGF1R*: in these cases, MAF was similar or even smaller in CKDGen than in 342 CHRIS (Fig. 2). The presence of un-modeled sample structure causing genomic inflation can be 343 excluded as relatedness was appropriately modeled. We can also exclude the presence of 344 genetic admixture as the CHRIS study was conducted in a small area, on a local population of  $345$  homogeneous ancestry<sup>15,39-41</sup>. Differences in LD structure between the local and the overall 346 population can also be excluded as regional association plots showed similar shapes between 347 CHRIS and CKDGen. Epistatic gene-gene interaction would be a further possibility that cannot 348 be easily verified. The most plausible remaining reasons would be the presence of local effect 349 modifiers or gene-by-environment interaction.

350 Mediation analysis based on commonly measured biochemical and anthropometric traits 351 provided limited answers in this respect but highlighted relevant mechanisms at three loci. The 352 first finding was the identified presence of partial mediation of serum magnesium levels on the 353 association of eGFRcrea with the *SHROOM3* locus. Genetic variants at *SHROOM3* have been 354 associated with CKD<sup>8,9</sup>, reduced eGFRcrea<sup>9</sup>, increased albumin-to-creatinine ratio<sup>10</sup>, and low 355 serum magnesium levels<sup>11</sup>. SHROOM3 is necessary to maintain the glomerular filtration barrier 356 integrity<sup>42</sup>. Variants in this gene have been shown to be associated with increased risk of CKD<sup>43</sup>, 357 likely through disruption of the transcription factor TCF7L2 in podocyte cells. At the same locus, 358 *FAM47E* is highly expressed in the human glomeruli and its transcription levels were associated 359 with eGFRcrea<sup>44</sup>. Additional genes in this locus include *STBD1* and *CCDC158*, for which no 360 connection with kidney function was demonstrated. The kidney is one of the primary regulators 361 of serum magnesium concentration. It has been suggested that *SHROOM3* might increase serum magnesium levels through decreased renal magnesium excretion45 362 . At the *SHROOM3* 363 rs13146355 SNP, a previous GWAS on serum magnesium showed that the allele related with 364 lower magnesium levels was associated with higher eGFRcrea levels<sup>37</sup>. The authors observed 365 that the rs13146355 association with magnesium did not change when adjusting for eGFRcrea, 366 suggesting pleiotropic independent effects. In our analysis, the effect of rs13146355 on 367 eGFRcrea was reduced by 11% when adjusting for magnesium, suggesting partial mediation 368 and thus the presence of partially overlapping mechanisms. Deeper analyses at the molecular 369 level are warranted to identify the relevant mechanism.

370 A similar situation was observed at *SLC34A1* which, in addition to eGFRcrea<sup>35</sup>, was also 371 previously associated with aPTT in a GWAMA of 9240 European ancestry individuals $36$ 

372 including participants from the same areas where the CHRIS study was sampled. By quantifying 373 the clotting time from the activation of factor XII (*F12*) until the formation of a fibrin clot, aPTT is 374 a measure of the integrity of the intrinsic and common coagulation pathways<sup>46</sup>. The observed 375 mediation, in which adjustment for aPTT increases the SNP-eGFRcrea association by 21%, is 376 likely related to the proximity between *SLC34A1* and the coagulation factor gene *F12*. The LD at 377 this locus is compatible with the presence of common haplotypes tagging both genes, inducing 378 pleiotropic independent effects on eGFRcrea and aPTT.

379 An additional relevant finding was the presence of an interaction between two SNPs at 380 *STC1* and TSH levels. *STC1* is chiefly expressed in the thyroid gland 381 (https://gtexportal.org/home/gene/STC1). It is also highly expressed in the kidney, where it is 382 exclusively expressed in the collecting duct<sup>47</sup>.  $STC1$  is also associated with urate and urea 383 Ievels and is involved in the physiological response to dehydration and protein-rich diet<sup>47</sup>. The 384 *STC1*-encoded protein, stanniocalcin-1, is involved in phosphate reabsorption in the kidney 385 proximal tubules and in multiple pathophysiological mechanisms including ischemic kidney 386 injury<sup>48</sup>. Stanniocalcin-1 behaves like an endocrine hormone, with both autocrine and paracrine 387 functions. Our observation of a SNP effect on eGFRcrea depending on TSH levels would 388 suggest that altered thyroid function levels might affect Stanniocalcin-1 levels with consequent 389 effect on kidney function phenotypes. While intriguing, this hypothesis should be verified by 390 appropriate studies.

391 Our study had both strengths and limitations. The exploitation of a local homogeneous 392 population sample was at the same time the most relevant strength and limitation of our study. 393 While homogeneity may enhance the identification of specific genetic associations, it may also 394 hinder the possibility to explain the underlying reasons of the observed larger effects compared 395 to the average European ancestry population. The availability of a very large number of clinical 396 parameters has allowed us to conduct an exhaustive and unbiased screening on potential 397 mediation mechanisms. However, the analyzed traits lacked molecular specificity to identify 398 underlying mechanisms. Given eGFRcrea might also reflect creatinine metabolism in addition to 399 kidney function, another limitation of our study was the lack of additional kidney function 400 markers such as cystatin C or BUN. For this reason, we limited our analyses to loci whose 401 kidney function relevance was already demonstrated by previous studies<sup>17</sup>. Assessment of 402 environmental exposures may also be a tool to explain the observed larger effects and would be 403 ground for further research. Finally, our choice of adjustment for multiple testing is also worth a 404 brief reflection. We have considered 147 loci that were already validated by at least one

405 previous study through discovery and independent replication<sup>17</sup>, with several of the same loci 406 being already reported previously<sup>35,49,50</sup>. As such, they wouldn't need further validation and a 407 nominal significance level would be commonly accepted for statistical testing. However, the aim 408 of our analysis was to identify loci with substantially large effect in the CHRIS study to further 409 conduct meaningful mediation analyses. For this reason, we choose to penalize the significance 410 level by the number of independent loci. To us, this seems to be a sensible choice also by the 411 fact that 147 independent tests covered 98% of the total variability of the 6337 SNPs in strong 412 LD observed overall.

413 In conclusion, our study has identified loci that have particularly large effect on kidney 414 function in the specific Alpine population sample considered in this study, namely *CASZ1*, 415 *IGF1R*, *GAB2*, and *DDX1*. Allele frequency and LD analyses did not explain the observed larger 416 effects nor did the extensive mediation analyses conducted. On the other hand, we showed that 417 the effects of *SHROOM3* and *SLC34A1* on eGFRcrea are partially mediated by serum 418 magnesium and aPTT, respectively. Finally, the observed *STC1*-TSH interaction implicates 419 thyroid function involvement, which might have been favored by the high burden of thyroid-420 related diseases in the region. Further investigations are warranted to link the identified loci to 421 environmental and molecular characteristics of specific population samples that may elucidate 422 mechanisms not otherwise identifiable in large genetic meta-analyses.

- 423
- 424

#### 425 **Acknowledgements**

426 The CHRIS study is a collaborative effort between the Eurac Research Institute for Biomedicine 427 and the Healthcare System of the Autonomous Province of Bozen/Bolzano. We thank all study 428 participants, the general practitioners, the personnel of the Hospital of Schlanders/Silandro, the 429 field study team and the personnel of the CHRIS Biobank (BRIF code BRIF6107) for their 430 support and collaboration. Extensive acknowledgement is reported at 431 https://translationalmedicine.biomedcentral.com/articles/10.1186/s12967-015-0704-9.

432

### 433 **Funding**

434 The CHRIS study was funded by the Department of Innovation, Research and University of the 435 Autonomous Province of Bolzano-South Tyrol. This work was carried out within the TrainCKDis

- 436 project, funded by the European Union's Horizon 2020 research and innovation programme 437 under the Marie Skłodowska-Curie grant agreement H2020-MSCA-ITN-2019 ID:860977 438 (TrainCKDis).
- 439

### 440 **Author contributions**

- 441 Conceptualization of the research project: C.P., D.G.
- 442 Recruitment and study management: M.G., P.P.P., C.P.
- 443 Bioinformatics: D.G., E.K., D.E., C.F.
- 444 Data quality control and harmonization: M.G., L.B., L.F.
- 445 Statistical Analysis: D.G.
- 446 Results interpretation: D.G., C.P., C.F., D.E., M.G., L.F., R.F.
- 447 Manuscript drafting: D.G., C.P.
- 448 Manuscript critical revision: D.E., E.K., R.F., L.F., L.B., M.G., D.J.M.P., P.P.P., C.F., D.G., C.P.
- 449
- 450

### 451 **Competing interests**

- 452 The authors declare no competing financial interests.
- 453

#### 454 **Data availability**

455 The data used in the current analyses can be requested with an application to 456 access.request.biomedicine@eurac.edu at the Eurac Research Institute for Biomedicine.

### 457 **References**

- 459 1 Eckardt, K. U. *et al.* Evolving importance of kidney disease: from subspecialty to 460 global health burden. *Lancet* **382**, 158-169, doi:10.1016/s0140-6736(13)60439-0 461 (2013).
- 462 2 Foreman, K. J. *et al.* Forecasting life expectancy, years of life lost, and all-cause 463 and cause-specific mortality for 250 causes of death: reference and alternative 464 scenarios for 2016-40 for 195 countries and territories. *Lancet* **392**, 2052-2090, 465 doi:10.1016/s0140-6736(18)31694-5 (2018).
- 466 3 Global, regional, and national burden of chronic kidney disease, 1990-2017: a 467 systematic analysis for the Global Burden of Disease Study 2017. *Lancet* **395**, 468 709-733, doi:10.1016/s0140-6736(20)30045-3 (2020).
- 469 4 Naik, R. P. *et al.* Association of sickle cell trait with chronic kidney disease and 470 albuminuria in African Americans. *Jama* **312**, 2115-2125, 471 doi:10.1001/jama.2014.15063 (2014).
- 472 5 Brück, K. *et al.* CKD prevalence varies across the European general population. 473 *Journal of the American Society of Nephrology* **27**, 2135, 474 doi:10.1681/ASN.2015050542 (2016).
- 475 6 Köttgen, A. & Pattaro, C. The CKDGen Consortium: ten years of insights into the 476 genetic basis of kidney function. *Kidney Int* **97**, 236-242, 477 doi:10.1016/j.kint.2019.10.027 (2020).
- 478 7 Stanzick, K. J. *et al.* Discovery and prioritization of variants and genes for kidney 479 function in >1.2 million individuals. *Nature Communications* **12**, 4350, 480 doi:10.1038/s41467-021-24491-0 (2021).
- 481 8 Chong, Jessica X. *et al.* The Genetic Basis of Mendelian Phenotypes: 482 Discoveries, Challenges, and Opportunities. *The American Journal of Human*  483 *Genetics* **97**, 199-215, doi:https://doi.org/10.1016/j.ajhg.2015.06.009 (2015).
- 484 9 Montasser, M. E. *et al.* Genetic and functional evidence links a missense variant 485 in B4GALT1 to lower LDL and fibrinogen. *Science* **374**, 1221-1227, 486 doi:10.1126/science.abe0348 (2021).
- 487 10 Hamet, P. *et al.* PROX1 gene CC genotype as a major determinant of early onset 488 of type 2 diabetes in slavic study participants from Action in Diabetes and 489 Vascular Disease: Preterax and Diamicron MR Controlled Evaluation study. *J*  490 *Hypertens* **35 Suppl 1**, S24-s32, doi:10.1097/hjh.0000000000001241 (2017).
- 491 11 Humphries, E. M. *et al.* Genome-wide significant risk loci for mood disorders in 492 the Old Order Amish founder population. *Mol Psychiatry*, doi:10.1038/s41380- 493 023-02014-1 (2023).
- 494 12 Pattaro, C. *et al.* The Cooperative Health Research in South Tyrol (CHRIS) 495 study: rationale, objectives, and preliminary results. *Journal of Translational*  496 *Medicine* **13**, 348, doi:10.1186/s12967-015-0704-9 (2015).
- 497 13 Pattaro, C. *et al.* Genome-wide linkage analysis of serum creatinine in three 498 isolated European populations. *Kidney International* **76**, 297-306, 499 doi:https://doi.org/10.1038/ki.2009.135 (2009).
- 500 14 Pattaro, C. *et al.* A meta-analysis of genome-wide data from five European 501 isolates reveals an association of COL22A1, SYT1, and GABRR2with serum

- 502 creatinine level. *BMC Medical Genetics* **11**, 41, doi:10.1186/1471-2350-11-41 503 (2010).
- 504 15 Gögele, M., Pattaro, C., Fuchsberger, C. & Pramstaller, P. P. Fertility pattern and 505 family structure in three Alpine settlements in South Tyrol (italy): marriage 506 cohorts from 1750 to 1949. *J Biosoc Sci* **41**, 697-701, 507 doi:10.1017/s0021932009003423 (2009).
- 508 16 Bolzano, A. o. t. P. o. *Prevalence of the Chronic Diseases*, 509 <https://www.provincia.bz.it/salute-benessere/osservatorio-salute/diffusione-510 delle-malattie-croniche.asp> (2019).
- 511 17 Wuttke, M. *et al.* A catalog of genetic loci associated with kidney function from 512 analyses of a million individuals. *Nat Genet* **51**, 957-972, doi:10.1038/s41588- 513 019-0407-x (2019).
- 514 18 Noce, D. *et al.* Sequential recruitment of study participants may inflate genetic 515 heritability estimates. *Hum Genet* **136**, 743-757, doi:10.1007/s00439-017-1785-8 516 (2017).
- 517 19 Bates, D., Mächler, M., Bolker, B. & Walker, S. Fitting Linear Mixed-Effects 518 Models Using lme4. *Journal of Statistical Software* **67**, 1 - 48, 519 doi:10.18637/jss.v067.i01 (2015).
- 520 20 Levey, A. S. *et al.* A new equation to estimate glomerular filtration rate. *Ann*  521 *Intern Med* **150**, 604-612, doi:10.7326/0003-4819-150-9-200905050-00006 522 (2009).
- 523 21 Pattaro, C. *et al.* Estimating the glomerular filtration rate in the general population 524 using different equations: effects on classification and association. *Nephron Clin*  525 *Pract* **123**, 102-111, doi:10.1159/000351043 (2013).
- 526 22 O'Connell, J. *et al.* A general approach for haplotype phasing across the full 527 spectrum of relatedness. *PLoS Genet* **10**, e1004234, 528 doi:10.1371/journal.pgen.1004234 (2014).
- 529 23 Das, S. *et al.* Next-generation genotype imputation service and methods. *Nat*  530 *Genet* **48**, 1284-1287, doi:10.1038/ng.3656 (2016).
- 531 24 Yang, J., Lee, S. H., Goddard, M. E. & Visscher, P. M. GCTA: a tool for genome-532 wide complex trait analysis. *Am J Hum Genet* **88**, 76-82, 533 doi:10.1016/j.ajhg.2010.11.011 (2011).
- 534 25 Kang, H. M. *et al.* Variance component model to account for sample structure in 535 genome-wide association studies. *Nat Genet* **42**, 348-354, doi:10.1038/ng.548 536 (2010).
- 537 26 Devlin, B. & Roeder, K. Genomic control for association studies. *Biometrics* **55**, 538 997-1004 (1999).
- 539 27 Nolte, I. M. Metasubtract: an R-package to analytically produce leave-one-out 540 meta-analysis GWAS summary statistics. *Bioinformatics* **36**, 4521-4522, 541 doi:10.1093/bioinformatics/btaa570 (2020).
- 542 28 Zhao, H. *et al.* CrossMap: a versatile tool for coordinate conversion between 543 genome assemblies. *Bioinformatics* **30**, 1006-1007, 544 doi:10.1093/bioinformatics/btt730 (2014).
- 545 29 Gögele, M. *et al.* Methods for Meta-Analyses of Genome-wide Association 546 Studies: Critical Assessment of Empirical Evidence. *American Journal of*  547 *Epidemiology* **175**, 739-749, doi:10.1093/aje/kwr385 (2012).

- 548 30 Quick, C. *et al.* emeraLD: rapid linkage disequilibrium estimation with massive 549 datasets. *Bioinformatics* **35**, 164-166, doi:10.1093/bioinformatics/bty547 (2019).
- 550 31 Kamat, M. A. *et al.* PhenoScanner V2: an expanded tool for searching human 551 genotype-phenotype associations. *Bioinformatics* **35**, 4851-4853, 552 doi:10.1093/bioinformatics/btz469 (2019).
- 553 32 Sollis, E. *et al.* The NHGRI-EBI GWAS Catalog: knowledgebase and deposition 554 resource. *Nucleic Acids Res* **51**, D977-d985, doi:10.1093/nar/gkac1010 (2023).
- 555 33 Teumer, A. *et al.* Genome-wide analyses identify a role for SLC17A4 and AADAT 556 in thyroid hormone regulation. *Nature Communications* **9**, 4455, 557 doi:10.1038/s41467-018-06356-1 (2018).
- 558 34 Köttgen, A. *et al.* Multiple loci associated with indices of renal function and 559 chronic kidney disease. *Nat Genet* **41**, 712-717, doi:10.1038/ng.377 (2009).
- 560 35 Köttgen, A. *et al.* New loci associated with kidney function and chronic kidney 561 disease. *Nat Genet* **42**, 376-384, doi:10.1038/ng.568 (2010).
- 562 36 Tang, W. *et al.* Genetic associations for activated partial thromboplastin time and 563 prothrombin time, their gene expression profiles, and risk of coronary artery 564 disease. *Am J Hum Genet* **91**, 152-162, doi:10.1016/j.ajhg.2012.05.009 (2012).
- 565 37 Meyer, T. E. *et al.* Genome-wide association studies of serum magnesium, 566 potassium, and sodium concentrations identify six Loci influencing serum 567 magnesium levels. *PLoS Genet* **6**, doi:10.1371/journal.pgen.1001045 (2010).
- 568 38 Volpato, C. B. *et al.* Linkage and association analysis of hyperthyrotropinaemia in 569 an Alpine population reveal two novel loci on chromosomes 3q28-29 and 6q26- 570 27. *J Med Genet* **48**, 549-556, doi:10.1136/jmg.2010.088583 (2011).
- 571 39 Pattaro, C. *et al.* The genetic study of three population microisolates in South 572 Tyrol (MICROS): study design and epidemiological perspectives. *BMC Med*  573 *Genet* **8**, 29, doi:10.1186/1471-2350-8-29 (2007).
- 574 40 Gögele, M. *et al.* Heritability analysis of life span in a semi-isolated population 575 followed across four centuries reveals the presence of pleiotropy between life 576 span and reproduction. *J Gerontol A Biol Sci Med Sci* **66**, 26-37, 577 doi:10.1093/gerona/glq163 (2011).
- 578 41 Riegler, A., Marroni, F., Pattaro, C., Gueresi, P. & Pramstaller, P. P. Isolation and 579 marriage patterns in four South Tyrolean villages (Italy) during the nineteenth 580 century. *J Biosoc Sci* **40**, 787-791, doi:10.1017/s0021932007002568 (2008).
- 581 42 Yeo, N. C. *et al.* Shroom3 contributes to the maintenance of the glomerular 582 filtration barrier integrity. *Genome Res* **25**, 57-65, doi:10.1101/gr.182881.114 583 (2015).
- 584 43 Prokop, J. W. *et al.* Characterization of Coding/Noncoding Variants for 585 SHROOM3 in Patients with CKD. *J Am Soc Nephrol* **29**, 1525-1535, 586 doi:10.1681/asn.2017080856 (2018).
- 587 44 Ledo, N. *et al.* Functional genomic annotation of genetic risk loci highlights 588 inflammation and epithelial biology networks in CKD. *J Am Soc Nephrol* **26**, 692- 589 714, doi:10.1681/asn.2014010028 (2015).
- 590 45 Larsson, S. C., Drca, N. & Michaëlsson, K. Serum Magnesium and Calcium 591 Levels and Risk of Atrial Fibrillation. *Circulation: Genomic and Precision*  592 *Medicine* **12**, e002349, doi:doi:10.1161/CIRCGEN.118.002349 (2019).

- 593 46 Kitchen, S., McCraw, A. & Echenagucia, M. Diagnosis of hemophilia and other 594 bleeding disorders. *World Federation of Hemophilia* (2010).
- 595 47 Park, J. *et al.* Single-cell transcriptomics of the mouse kidney reveals potential 596 cellular targets of kidney disease. *Science* **360**, 758-763, 597 doi:10.1126/science.aar2131 (2018).
- 598 48 Zhao, F. *et al.* Expression, function and clinical application of stanniocalcin-1 in 599 cancer. *J Cell Mol Med* **24**, 7686-7696, doi:10.1111/jcmm.15348 (2020).
- 600 49 Pattaro, C. *et al.* Genome-Wide Association and Functional Follow-Up Reveals 601 New Loci for Kidney Function. *PLOS Genetics* **8**, e1002584, 602 doi:10.1371/journal.pgen.1002584 (2012).
- 603 50 Pattaro, C. *et al.* Genetic associations at 53 loci highlight cell types and biological 604 pathways relevant for kidney function. *Nature Communications* **7**, 10023, 605 doi:10.1038/ncomms10023 (2016).

### 607 **Tables**

 $\mathbb{R}^2$ 

608 **Table 1**. Main characteristics of the 10,146 study individuals. Additional clinical characteristics 609 are described in Supplementary Table 1.



610 Abbreviations: IQR, Interquartile range; TSH, Thyroid-stimulating hormone; FT3, Free triiodothyronine;<br>611 FT4, Free thyroxine; Mg, serum magnesium; aPTT, activated partial thromboplastin time.

611 FT4, Free thyroxine; Mg, serum magnesium; aPTT, activated partial thromboplastin time.

612 **Table 2**. The 11 loci identified from the CKDGen Consortium GWAS that showed significant effects in CHRIS. Loci were considered 613 replicated if any variant in strong LD with the CKDGen lead variant was significantly associated with ln(eGFRcrea) in CHRIS.

614 Consequently, for each locus, reported are either the results on the CKDGen lead variant or the results of the replicated variant in the

615 locus when the lead variant did not replicate itself (see Methods).



616  $^{-1}$ Trans-ethnic and European ancestry CKDGen results after subtracting the effect of 4661 CHRIS participants included in the 617 CKDGen meta-analysis.<br>618 Abbreviations: Chr. chror

618 Abbreviations: Chr, chromosome; Pos, position; EA, effect allele; OA, other allele; EAF, effect allele frequency; b, coefficient of association; SE, standard error of b.

620 \*Replication of a variant in strong LD with the CKDGen lead variant: in these cases, the replicated and not the CKDGen lead variant 621 is reported. See Supplementary Table S2 for lead variant comparisons.

is reported. See Supplementary Table S2 for lead variant comparisons.

622 **Table 3** Results of the mediation analysis at *SHROOM3* and *SLC34A1*. Extensive mediation analysis results for all loci and all traits 623 are reported in Supplementary Table S4.



624 Abbreviations: Chr, chromosome; Pos, position; EA, effect allele; OA, other allele; b, coefficient of association; SE, standard error of 625 b; Mg, Magnesium; aPTT, activated Partial Prothrombin Time. b; Mg, Magnesium; aPTT, activated Partial Prothrombin Time.

### 626 **Figures**



627

628 **Figure 1. Flowchart of the mediation analysis.** Abbreviations: Mg, serum magnesium; aPTT, 629 activated partial thromboplastin time.



630

631 **Figure 2. Effect sizes with 95% confidence intervals for the most associated variants at**  632 **each locus in CKDGen and CHRIS following harmonization to the eGFRcrea-lowering**  633 **allele.** The effect is meant per copy of the effect allele on the natural logarithm of eGFRcrea in 634 ml/min/1.73m<sup>2</sup> (y-axis). For *CASZ1*, *DDX1*, *PIP5K1B*, *GAB2*, and *IGF1R* the magnitude of the 635 effect in CHRIS was larger than in CKDGen.



### 636

637 **Figure 3. Comparison of the characteristics of all 163 variants in the 11 replicated loci in in**  638 CKDGen versus CHRIS after alignment of the effect alleles. Panel A: Variance of age- and 639 sex-adjusted In(eGFRcrea) in CHRIS versus CKDGen EUR explained by the lead variants at 640 each of the 147 loci. Replicated loci are labeled with the locus name. **Panel B**: The ratio 641 between CHRIS and CKDGen minor allele frequencies (MAF, x-axis) is plotted against the ratio 642 between CHRIS and CKDGen effect estimates (y-axis). Effects are expressed in terms of 643 change of the natural logarithm of eGFRcrea in ml/min/1.73m<sup>2</sup> per copy of the effect allele.



644





651

652 **Figure 5. Interaction of ln(eGFRcrea)-associated variants with TSH levels.** Effects of *STC1* SNPs rs819185 (P=0.00177; **Panel** 

653 **A**) and rs819196 (P=0.00154; **Panel B**) are larger at lower TSH levels.

## 654 **Supplementary Material**

### 655 **Table of Contents**



674 **Supplementary method.** Quantile normalization of the 70 health traits used in the mediation 675 analysis.

676 We used *normalize2Reference* function in the caret R package version 6.0-34 (the function is 677 available in the later versions here: https://github.com/topepo/caret/tree/master/deprecated). 678 Each trait was measured partially with an older method and partially with a newer, most recent  $679$  method. The observations from the newer method (method  $= 1$ ) were set as the reference to 680 derive the quantiles of the trait distribution on which to standardize the observations from the 681 older method (method  $= 0$ ). We then replaced the observation from the older method with the 682 standardized ones and included together with the values from the newer method.

683 **Notation:**

```
684 - trait: the quantitative variable to which quantile normalization was applied;
```
- 685 **method:** the newer method for measuring the trait (1); the older method (0);
- 686 **df:** dataframe; the data in which the trait of interest is available

```
687
```

```
688 library(caret)
```

```
689 quantile_norm <- normalize2Reference(
```

```
690 data = df[df$method == 0, "trait"],
```

```
691 refData = quantile(
```
 $692$  df [df $$$ method == 1, "trait"],

```
693 probs = \text{seq}(0, 1, \text{length.out} = \text{length}(df[df\text{Smethod} == 0,
```

```
694 "trait"])), 
695 na.rm = TRUE,
```

```
696 names = TRUE,
```

```
697 type = 7,
```

```
698 digits = 7),
```

```
699 ties = TRUE)
```

```
700
```
701 # Creating a new variable for the quantile normalized trait

```
702 df$trait std <- df$trait
```
703 # Replacing non-transformed values with the quantile-normalized values

```
704 df [df$method == 0, "trait std"] <- quantile norm
```
705 **Supplementary Figure S1.** Cumulative variance of 6337 variants over 147 loci explained by 706 principal components in the CHRIS study. Adjusting for 147 independent tests covers 98% of 707 the cumulative variance (red dot).



- 709 **Supplementary Figure S2.** Fitting PC-adjusted simple linear models came for practical reasons
- 710 after observing substantial equivalence with kinship-adjusted linear mixed models obtained with
- 711 EMMAX.



- 713 **Supplementary Figure S3.** Quantile-quantile (QQ) plot of the P-values from the GWAS of
- 714 In(eGFRcrea) in the CHRIS study.



- 716 **Supplementary Figure S4.** Regional association plots for the 11 replicated loci. Highlighted in
- 717 purple is the most associated SNP in the CKDGen GWAS meta-analysis. All SNP positions are
- 718 referred to the NCBI Build 38. Plots were generated with LocusZoom version 1.4 (Pruim RJ, et
- 719 al., Bioinformatics, 2010. 26(18): 2336-7).
- 720 \* indicates cases where not the CKDGen lead SNP but a proxy of it was replicated in the CHRIS 721 study.
- 722
- 

723 Top CHRIS SNP: rs74748843 (1:10,670,853) at *CASZ1* 



# 725 Top CHRIS SNP: rs807624 (2:15,642,347) at *DDX1*





728 Top CHRIS SNP: rs28817415 (4:76,480,299) at *SHROOM3*



# 730 Top CHRIS SNP: rs1362800\* (5:39,378,013) at *DAB2\**



731 732

733 Top CHRIS SNP: rs3812036 (5:177,386,403) at *SLC34A1*



# 735 Top CHRIS SNP: rs6973656\* (7:77,793,266) at *TMEM60\**



736 737

## 738 Top CHRIS SNP: rs34861762\* (8:23,890,907) at *STC1\**



## 740 Top CHRIS SNP: rs2039424 (9:68,817,258) at *PIP5K1B*







743 Top CHRIS SNP: rs11237450\* (11:78,312,310) at *GAB2\**



# 745 Top CHRIS SNP: rs59646751 (15:98,733,292) at *IGF1R*





748 Top CHRIS SNP: rs77924615 (16:20381010) at *PDILT*



750 **Supplementary Figure S5.** Comparison of effect size and standard error ratio for the variants 751 in the model regressing ln(eGFRcrea) on age, sex, FT3 (or FT4), genetic variants with and 752 without adjusting for municipality.

753

